Sanofi-Aventis/Altana's Asthma Therapy Alvesco Is "Approvable"
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says the review decision came directly from ODE II rather than the Division of Pulmonary & Allergy Drug Products. Aventis had touted Alvesco as one of six product launches that would drive organic growth during its attempts to fend off Sanofi's merger bid.
You may also be interested in...
Nycomed Seeks U.S. Partner To Promote Alvesco Asthma Inhaler And Intranasal Omnaris
FDA approved Alvesco to treat asthma in patients 12 and older Jan. 10, the Swiss pharma tells “The Pink Sheet” DAILY.
Nycomed Seeks U.S. Partner To Promote Alvesco Asthma Inhaler And Intranasal Omnaris
FDA approved Alvesco to treat asthma in patients 12 and older Jan. 10, the Swiss pharma tells “The Pink Sheet” DAILY.
Where’s Menactra? No Word From Sanofi-Aventis As User Fee Date Passes
The estimated user fee deadline for the meningococcal conjugate vaccine was Oct. 18. FDA says the vaccine is not currently a licensed product; Sanofi-Aventis has not announced an action by the agency.